Basal Plasma Lithium Levels and Suicidal Events

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Montpellier

About this trial

Suicidal behavior is a major public health issue and there are currently no specific treatments for it.

However, lithium, the reference treatment for bipolar disorder, have been shown to be effective in preventing suicidal risk.

Apart from drug treatments, lithium is present in our environment and its levels varies from one individual to another, depending, especially, on diet.

Knowing that patients with a mood disorder generally have a poor lifestyle and a less rich and varied diet than the general population, variations in basal lithium levels can be expected in these patients.

Eligibility criteria

Qualifiers

18 years old or over

Current major depressive episode according to the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria

No lithium-based treatment over the last 12 months

For suicide attempters/ideations only : suicidal event over the last 12 months

Disqualifiers

Lifetime diagnosis of schizoaffective disorder, schizophrenia or psychosis

Pregnancy or breastfeeding

Deprivation of freedom (by judicial or administrative decision)

Legal protection measure (guardianship or curators)

Trial design

Treatments tested in this trial

  • Blood sample

Treatment groups

158 Participants
are divided into 2 treatment groups